You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


AZ kicks off PhI trial of potential COVID-19 therapy

AstraZeneca has dosed the first participants in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) being developed for prevention and treatment of COVID-19.